As a mother of three sons with cystic fibrosis, Mary along with her husband, Harry, was determined to do all she could to find a cure.
Senate Caucus will work with House Caucus to raise awareness, advance policies and support research
|
5 min read
On Mar. 11, the Cystic Fibrosis Foundation presented the Alex, Jena and Dream Big Awards to leaders in the CF community for their dedication to the Foundation's mission of finding a cure.
|
4 min read
Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) will provide up to $3 million through a drug development award to Swiss pharmaceutical company Polyphor Ltd. to continue clinical trials of a potential anti-inflammatory drug. The drug, POL6014, inhibits the activity of an enzyme that can destroy lung tissue if produced in excess.
|
2 min read
The Cystic Fibrosis Foundation's tenth annual March on the Hill saw more than 80 volunteer advocates from 34 states convene in Washington, D.C. to speak with their members of Congress about cystic fibrosis and ways that elected officials can support the CF community and our search for a cure.
|
4 min read
On Feb. 25, members of CF Foundation leadership and advocates from the CF community joined President Obama, National Institutes of Health (NIH) Director Francis S. Collins, Food and Drug Administration (FDA) Commissioner Robert M. Califf, White House staff and other stakeholders at the Precision Medicine Initiative Summit (PMI), hosted by the White House.
|
3 min read
On Feb. 24 and 25, the Cystic Fibrosis Foundation presented three Legislative Champion Awards to Senator Ron Wyden (D-Ore.), Senator Orrin Hatch (R-Utah) and Congressman Lloyd Doggett (D-Texas) for their ardent support of the CF community and their sponsorship of S. 139/H.R. 209, the Ensuring Access to Clinical Trials Act.
|
3 min read
Feb. 25 will mark the tenth anniversary of the Cystic Fibrosis Foundation's signature advocacy event, March on the Hill. Nearly 75 advocates will come together in Washington, D.C. to meet with their elected officials on behalf of their loved ones, who are living with cystic fibrosis.
|
2 min read
The U.S. Food and Drug Administration (FDA) has decided not to approve the use of ivacaftor (Kalydeco®) to treat people with cystic fibrosis ages 2 and older who have one of 23 rare CF mutations, known as “residual function” mutations.
|
2 min read